It is an unlisted event never seen with Flu ever and not neuropathy. Oh contrar, it is obviously not Flu and will be observed in all JCAR trials with sufficient patient numbers. The brain and CSF is being targeted as autopsy and imaging would show.
It will take months for the deal to close so you won't get the full price and arbitrage until then, unless the market is expecting a higher bid so the floor moves up. In the meantime, the deal could collapse, a safety or regulatory issue could fall from the sky,,President Sanders could kill the deal...no one will fault you for taking profits and losing a penny, but Novaman could guide us when she wakes up from her seance with Riceen.
It's another vertical spread at 60, 65, 70,,, According to the past pattern, big news after the close.
What did we learn from your long-winded post other than based on your impeccable writing and use of apostrophe that you are not from the USA, but welcome to the savant Yahoo family.
Sanofi did itself no favors with the low-ball offer when for a modest amount more at 65 they could have entered into exclusive negotiations. Now they will have to enter a bidding process whereby the highest bidder or the best bid as deemed by the BOD will enter into exclusive negotiations for a deal. At the end of the day there is nothing to stop a hostile bidder other than whatever break-up fee is negotiated but it would take a home run like 90 per share to convince the board to terminate a deal at say 75.
And how did that work out? No, those investors are still angry about that and won't accept this time around. Besides that is the wrong tactic to apply in this situation with multiple bidders. Grandpa needs to get off the pot for the children.
Seemed to be an over-the-top amount of hype leaked today, so expect sell recommendation tomorrow off of the earnings report with the momentum of a 300 point drop in the DOW in an attempt to shake the trees and pick up some more shares on the cheap.
A good point but this particular analysis is from Sanofi's perspective and the Euro currency. When looking at the British Pound and tax rates, AstraZeneca, Glaxo and even Shire could have the advantage. Considering strategic fit or possibly desperation, Novartis may be ahead seeing it is selling its coveted position in Roche at market value, a stake that nobody in one's lifetime other than a family member will see again. European leadership usually does not think short term like immediate gratification, US institutional investors. So how can Medivation go for less than 75 without the BOD or JPM bungling the opportunity across the pond and waiting for the tax code and currency rates to change further. Tell everyone to make their final offers and be done with it. Make your own decisons and GL.
That would have been a reasonable starting point if Sanofi truly wanted to be in the game. So many companies make the mistake to initially offer the iimmediate value assessed by their financial advisors and based on current financial information that absurdly does not even take into account an upcoming quarterly report, which everyone knows will be positive and change projections. Forget about valuing the pipeline, because that is a soft skill that accountants don't have and an acquiring company would not want to share. Abbie, Gilead, and in years past Roche had it right... You come in BANG with shock and awe with your first offer, and if not accepted walk away moving on to your next target. Otherwise, the potential acquirer gets mired in the hem and haw for months of needless melodrama and loses the advantage versus one's competitors of striking first.
The Sanofi CEO statements sound so desperate and pathetic you would think AZN is closing the deal today and Medivation will give Sanofi the finger...but surely that winner who bought the 700 calls and hundreds more at lower prices would know best and is tanning on a beach of a tax free island.